← Evidence map

ArticleMedicina (Kaunas, Lithuania)2026

HER2-Low Versus HER2-Zero Breast Cancer in the Neoadjuvant Setting: Pathological Complete Response and Exploratory Survival Outcomes in a Single-Center Cohort.

Ümitcan Ateş et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

HER2-Low Versus HER2-Zero Breast Cancer in the Neoadjuvant Setting: Pathological Complete Response and Exploratory Survival Outcomes in a Single-Center Cohort. | OpenQuestion